Despite Being Costly, Ozempic, Wegovy Prescriptions Surge 300% Over Three Years
Portfolio Pulse from Vandana Singh
Prescriptions for diabetes and obesity drugs like Ozempic and Wegovy have surged 300% from early 2020 to the end of 2022, according to an analysis by Trilliant Health. Novo Nordisk's Ozempic accounted for over 65% of total prescriptions. Eli Lilly's Mounjaro and Novo Nordisk's Saxenda have also been prescribed. The surge can be attributed to their ability to induce significant weight loss. However, future prescription volumes depend on resolving supply shortages faced by Novo Nordisk and Eli Lilly in the U.S.
September 28, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's Mounjaro has also been prescribed. However, future prescription volumes depend on resolving supply shortages faced by the company in the U.S.
The mention of Eli Lilly's Mounjaro being prescribed indicates a demand for the drug. However, the company's ability to meet this demand is currently uncertain due to supply shortages. If resolved, this could lead to increased revenues for the company, potentially positively impacting its stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 70
POSITIVE IMPACT
Novo Nordisk's Ozempic dominates the market, accounting for over 65% of total prescriptions. However, future prescription volumes depend on resolving supply shortages faced by the company in the U.S.
The surge in prescriptions for Novo Nordisk's Ozempic indicates a strong demand for the drug. However, the company's ability to meet this demand is currently uncertain due to supply shortages. If resolved, this could lead to increased revenues for the company, potentially positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90